CSIMarket Company Name, Ticker, Competitors, else..
 
Revance Therapeutics Inc   (NASDAQ: RVNC)
Other Ticker:  
 
 
Price: $3.6800 $0.41 12.538%
Day's High: $3.7 Week Perf: 11.85 %
Day's Low: $ 3.60 30 Day Perf: 19.09 %
Volume (M): 11,242 52 Wk High: $ 7.56
Volume (M$): $ 41,370 52 Wk Avg: $4.48
Open: $3.66 52 Wk Low: $2.30



 Market Capitalization (Millions $) 384
 Shares Outstanding (Millions) 104
 Employees 534
 Revenues (TTM) (Millions $) 247
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) -122
 Capital Exp. (TTM) (Millions $) 4

Revance Therapeutics Inc
Revance Therapeutics Inc is a biotechnology company that specializes in developing and commercializing innovative therapies for cosmetic and therapeutic applications. The company was founded in 1999 and is headquartered in Newark, California.

Revance Therapeutics Inc's main focus is on developing a new generation of neuromodulators that has the potential to revolutionize the field of aesthetics and therapeutics. Neuromodulators are medications that can selectively disrupt nerve transmission, leading to muscle relaxation and paralysis. These medications are commonly used for cosmetic treatments such as smoothing out wrinkles and fine lines, but they can also treat various medical conditions such as dystonia, spasticity, and migraines.

The core technology platform of Revance Therapeutics Inc is its proprietary peptide technology called RT00 RT002 is a novel form of botulinum toxin type A that has been formulated to have a longer-lasting effect and a more targeted delivery. It has been shown to have a high degree of efficacy, durability, and safety, making it a promising alternative to older neuromodulators. Revance Therapeutics Inc has filed for regulatory approval in the United States, Europe, and Canada for RT002 as both a cosmetic therapy and a therapeutic agent.

In addition to its lead product, Revance Therapeutics Inc is also developing other products in its pipeline, including a topical formulation of RT002 for at-home use, and a dermal filler product that uses a novel approach to achieve long-lasting effects.

The company's management team includes seasoned executives and scientists with extensive experience in the biotechnology industry. Its board of directors includes experts in regulatory affairs, finance, and business development.

Revance Therapeutics Inc is at the forefront of innovation in the field of neuromodulators, and its commitment to bringing safe and effective treatments to patients and consumers has earned it a reputation as a rising star in the biotechnology industry.


   Company Address: 1222 Demonbreun Street, Suite 2000 Nashville 37203 TN
   Company Phone Number: 724-7755   Stock Exchange / Ticker: NASDAQ RVNC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -2.93%    
ABT        0.26% 
BMY        1.68% 
JNJ        1.77% 
MRK   -3.03%    
PFE   -1.87%    
• View Complete Report
   



Revance Therapeutics Inc

Revance Therapeutics Inc Reveals Modest Increase in Q1 2024 Performance

Revance Therapeutics Inc, a pharmaceutical company that specializes in the development of innovative aesthetic and therapeutic products, has experienced a significant decline in its stock price in April 2024. The stock has dropped by -21.99% this month, bringing the overall decrease to -38.81% in the past 90 days. This decline has also led the stock to reach its 52-week low.
The decline in Revance Therapeutics Inc's stock can be attributed to its poor financial performance in the first quarter of 2024. During this period, the company faced a loss of $-0.58 per share, a slight improvement from the previous year's loss of $-0.74 per share. However, the deficit increased from $-0.55 per share in the preceding reporting season.
Revance Therapeutics Inc

Revance Therapeutics Inc Reports Impressive Financial Results for Q4 2023

Revance Therapeutics Inc, a major player in the pharmaceutical industry, has reported its earnings for the fourth quarter of the 2023 fiscal year. The company showcased impressive financial results, with a decrease in loss per share and an improvement in earnings per share compared to the previous year. This positive trend was accompanied by a significant jump in revenue, indicating successful sales growth.
In the fourth quarter of 2023, Revance Therapeutics Inc reduced its loss per share from $-1.72 to $-0.55, demonstrating a considerable improvement. The company also witnessed a boost in earnings per share, rising from $-1.63 to an undisclosed amount from the previous financial reporting period.
Furthermore, the revenue for the fourth quarter of 2023 recorded a substantial increase of 39.819% to $69.80 million. This rise in revenue from $49.92 million in the corresponding financial reporting period a year ago indicates the company's ability to attract a larger customer base and generate higher sales. Sequentially, the revenue also improved by 22.938% from $56.78 million, further showcasing the company's ability to maintain growth momentum.
Revance Therapeutics Inc

Major Pharmaceutical Preparations Firm Reports Widening Losses in Latest Fiscal Period

The stock market has been buzzing with excitement lately, and one company that has been garnering attention is Revance Therapeutics Inc. Despite some negative figures in their recent fiscal period, there are several positive indicators that are worth noting.
Let's start with the revenue growth, which is an incredibly impressive feat. Revance Therapeutics Inc. managed to witness a staggering 95.678% increase in revenue, reaching an impressive $56.78 million. This is a significant jump from the $29.02 million reported in the same financial reporting period a year prior. Although there was a slight decrease of -2.336% sequentially from $58.13 million, it's important to view this in the context of the wider growth trend.
Revance Therapeutics Inc

Revance Therapeutics Inc Shatters Industry Norms with Staggering 104.928% Surge in Revenue, Outpacing Competitors



Revance Therapeutics Inc, a major player in the pharmaceutical preparations industry, has recently shared its financial results for the fiscal period ending June 30, 2023. The company witnessed a substantial increase in revenue, surpassing its industry counterparts. However, the firm also experienced a rise in losses during the same period. This article will outline the key facts and analyze the context surrounding Revance Therapeutics Inc's financial results.
Financial Results:
1. Revenue Growth: Revance Therapeutics Inc recorded an impressive year-on-year revenue rise of 104.928%, reaching $58.13 million for the fiscal period ending June 30, 2023. This growth significantly outpaced the average revenue rise of 0.89% seen within the Major Pharmaceutical Preparations industry.
Revance Therapeutics Inc

Revance Therapeutics Inc Achieves Remarkable 95.285% Revenue Surge, but Faces Challenging Shortfall in Q1 2023

Revance Therapeutics Inc recently reported a decent revenue growth in the January to March 31 2023 amounting to an impressive 95.285% to $49.33 million. However, contrary to the positive news, this development was not enough to completely turn the tide against their repeated losses. It still manifested a net shortfall of $-59.793 million, failing to meet expectations and instead falling short of the deficit of $-64.342 million in the same financial reporting period a year ago.
While this result may be quite positive from a dispassionate point of view, digging deeper reveals that the company had to cut losses to $-0.74 per share from $-0.94 in the same financial reporting period of the previous year. Add to that the fact that the Q4 revenue decreased by -1.182% from $49.92 million and EPS improved from $-1.72 per share, and the situation is far from ideal.






Revance Therapeutics Inc's Segments
Product revenue net    98.24 % of total Revenue
RHA Collection of dermal fillers    50.94 % of total Revenue
DAXXIFY    47.3 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com